v3.25.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities:    
Net loss $ (3,585,965) $ (5,087,029)
Stock-based compensation expense included in -    
General and administrative costs 418,422 773,203
Research and development costs
Increase (decrease) in -    
Advances on research and development contract services 78,016 69,001
Prepaid insurance (3,782) 32,108
Other prepaid expenses (75,653) 1,350
Accounts payable and accrued expenses (73,552) (73,976)
Research and development contract liabilities 77,978 (7,922)
Net cash used in operating activities (3,164,536) (4,293,265)
Cash flows from financing activities:    
Proceeds from sale of securities in registered direct offering, net of offering costs 3,137,039
Exercise of pre-funded common stock warrants 41
Exercise of common stock options 6,281
Net cash provided by financing activities 3,143,361
Cash:    
Net decrease (3,164,536) (1,149,904)
Balance at beginning of period 4,203,488 5,353,392
Balance at end of period 1,038,952 4,203,488
Supplemental disclosures of cash flow information:    
Interest 16,821 16,233
Income taxes

Source

HTML PDF
ZIP